Overview: Very Long Chain Fatty Acid TestIntroduction: The Very Long Chain Fatty Acid Test measures VLCFA to diagnose peroxisomal disorders, causing developmental delays. Aligned with 2023 AAP guidelines, it uses biochemical methods for high specificity, supporting metabolic screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in biochemistry for patients with suspected peroxisomal disorders.
Other Names: VLCFA Assay, Peroxisomal Disorder Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic accuracy.
Historical Milestone: VLCFA testing began in the 1980s with peroxisomal disorder research. Biochemical methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Measures VLCFA to diagnose peroxisomal disorders, guides treatment, and evaluates patients with developmental delays.
Test Parameters: 1. VLCFA Levels
Pretest Condition: No fasting required. Collect serum or plasma. Report history of developmental delays or neurological symptoms.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document developmental delays, seizures, or history of peroxisomal disorders. Include current medications or dietary history.
Consent: Written consent required, detailing the tests purpose, peroxisomal disorder implications, and risks of sample collection.
Procedural Considerations: Uses gas chromatography-mass spectrometry (GC-MS) to measure VLCFA levels (e.g., C26:0). Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for metabolic disorder diagnosis.
Factors Affecting Result Accuracy: Sample hemolysis or improper storage can affect results. Dietary factors may alter VLCFA levels.
Clinical Significance: Elevated VLCFA confirms peroxisomal disorders like Zellweger syndrome, guiding supportive therapy. Normal levels may require genetic testing.
Specialist Consultation: Consult a metabolic specialist or neurologist for result interpretation and treatment planning.
Additional Supporting Tests: Genetic testing, plasmalogen levels, or neurological imaging to confirm peroxisomal disorder diagnosis.
Test Limitations: Non-specific for disorder type; clinical correlation is needed. Sample quality affects sensitivity.
References: AAP Metabolic Guidelines, 2023; Journal of Inherited Metabolic Disease, Wanders RJ, 2022.
